Skip to content
etf.net

CANC

GradeDNASDAQ Global Market

Tema Oncology ETF

Themes · Tema · Inception 2023-08-14

$41.41−1.40 (−3.26%)

As of Sep 23, 2026, 2:20 PM EDT

History starts Aug 17, 2023.
Intraday session: down, 44 prints from 42.81 to 41.41. Range 41.27 to 42.81. Use the arrow keys to read each point.$42.00$42.5010 AM12 PM2 PM4 PM
Expense ratio
0.99%
Fund size
$209M
1Y return
+56.2%
Yield · Last 12 months
0.05%
Holdings
59
Volume · 30D
0M sh
NAV per share
$42.05
52W range
low $26.62high $47.00

The ETF.net CANC Grade

D

31/ 100

Rank 17 of 17 in Biotech & Genomics⁠

Confidence Medium

Six-pillar profile for CANC. Scores out of 100: Cost 0, Risk 62, Mission not scored, Tradability 33, Holdings 70, Durability 41. Strongest: Holdings (70). Weakest: Cost (0). Based on 5 of 6 pillars.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 31 of 100 sits in the D band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    FScore 0
    Category rank17/17 · bottom quartile

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    Not scored
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    BScore 62
    Category rank6/17 · top 35%

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    DScore 33
    Category rank11/17 · mid-pack

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    AScore 70
    Category rank6/17 · top 35%

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    CScore 41
    Category rank12/17 · mid-pack

Graded as of Sep 22, 2026 · Based on 5 of 6 pillars

Our read on CANC

ETF.net Research

DMost health care ETFs hand you the whole hospital: insurers, devices, dental supply. CANC goes straight at cancer, holding companies that draw at least half their revenue from oncology. A narrow, single-disease portfolio, launched in 2023.

Stated mandate

The Fund seeks long-term growth. Its principal strategy invests at least 80% of net assets in publicly listed companies deriving at least 50% of revenue from oncology.

Why people hold it

  1. 01The mandate is strict, not thematic window dressing: at least 80% of net assets in listed companies earning 50%+ of revenue from oncology.
  2. 02About 60 names, so each position carries real weight instead of cancer exposure getting diluted inside a 400-stock sector basket.
  3. 03A rare pure-play: the top-scoring funds in its health care cohort (VHT, FHLC, XLV) are broad sector baskets, not disease-specific portfolios.

Worth knowing

  1. 01Specialization costs: 0.99% a year, while broad health care index funds like VHT and XLV charge single-digit basis points.
  2. 02Thinly traded next to the category's giants, so the spread you pay entering and exiting can matter as much as the expense ratio.
  3. 03One disease, roughly 60 stocks. This is a slice of health care, not the sector, and it pays out at most a couple of times a year.

CANC Holdings

As of Sep 20, 2026, 6:07 AM
Asset class
Stocks
Holdings
59
Top-10 weight
39%
Largest holding
RVMD5.1%

Sectors

  • Health Care100.0%

Geography

  • United States80.26%
  • Switzerland10.05%
  • Denmark3.16%
  • United Kingdom3.13%
  • China2.06%
  • Germany0.77%
  • Singapore0.58%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001RVMDREVOLUTION MEDICINES INC5.12%55,664$11M169
002MRKMERCK & CO INC4.71%66,469$10M506
003COGTCOGENT BIOSCIENCES INC4.67%307,451$10M84
004LLYELI LILLY & CO4.56%8,209$9M569
005NOVN.SWNOVARTIS AG3.61%53,535$7M183
006ABBVABBVIE INC3.55%27,898$7M511
007BMYBRISTOL-MYERS SQUIBB CO3.50%115,234$7M460
008JNJJOHNSON & JOHNSON3.26%25,055$7M521
009ONCBEONE MEDICINES LTD3.22%19,049$7M35
010HALOHALOZYME THERAPEUTICS INC3.17%58,493$7M200
011GMABGENMAB A/S3.13%187,107$7M26
012RHHBYROCHE HOLDING AG3.12%119,440$6M18
013EXELEXELIXIS INC2.91%103,531$6M247
014CGONCG ONCOLOGY INC2.85%79,127$6M94
015IMNMIMMUNOME INC2.72%235,688$6M70

Showing 1–15 of 59 holdings

CANC Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

CANC$15,616
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. CANC $15,616. SPY $11,723. Use the arrow keys to read each point.$8,973$13,017$17,060Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for CANC. Periods over one year show the average yearly return.
PeriodCANC
Year to date+23.3%
1 month−4.0%
3 months+12.4%
1 year+56.2%
3 years+24.2%per year
5 yearsFund is under 5 years old—per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for CANC
YearReturn barCANC
2026 YTD+23.3%
2025+42.9%
2024−5.4%
2023+8.5%

History from Aug 17, 2023

CANC in the news

ETF.net Research hasn’t filed on CANC yet — coverage lands here as it’s written.

CANC Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
0.05%Last 12 months
Payout per share
$0.02Last 12 months
Last payment
$0.02 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2023–2026

One bar per payment. 3 payments from 2023 to 2026 YTD. Dec 13, 2023 $0.15; Dec 11, 2024 $0.73; Dec 10, 2025 $0.02. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Dec 10, 2025Dec 11, 2025$0.02
Dec 11, 2024Dec 12, 2024$0.73
Dec 13, 2023Dec 15, 2023$0.15

CANC Risk

How much the fund’s monthly returns vary, scaled to a year.
19.8%
Annualised · 36 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.85
vs 3-month T-bills · to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−28.0%
37 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.71
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

CANC Cost

Expense ratio0.99%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

Every other Biotech & Genomics fund charges less.

CANC costs $99.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.